Drop Seizure Frequency in Lennox-Gastaut Decreased With Cannabidiol

BOSTON – Adjunctive treatment with cannabidiol reduced the frequency of drop seizures in patients with treatment-refractory Lennox-Gastaut syndrome, according to results from 2 phase 3 studies reported at the 2017 American Academy of Neurology (AAN) Annual Meeting, April 22-28 in Boston.

The studies, GWPCARE3 and GWPCARE4, both multicenter, randomized, double-blind, placebo-controlled trials, evaluated the safety and efficacy of cannabidiol in patients with Lennox-Gastaut syndrome who were taking other antiepileptic drugs (AEDs).

In the GWPCARE3 study,1 Anup Patel, MD, of Nationwide Children’s Hospital in Columbus, Ohio, and colleagues conducted a dose-ranging trial in 225 patients aged 2 to 55 years with a confirmed diagnosis of Lennox-Gastaut syndrome with at least 8 drop seizures over a 4-week period at baseline and confirmed failure of at least 1 AED. 

Patients (median age=16 years; median monthly drop seizure frequency=85) were randomly assigned to receive either cannabidiol 20 mg/kg (n=76), 10 mg/kg (n=73), or placebo

... read more at: https://www.neurologyadvisor.com/aan-2017-coverage/aan-2017-cannabidiol-reduces-drop-seizures-in-lennox-gastaut-syndrome/article/652931/

by